GFGianpaolo Fogliatto

Gianpaolo Fogliatto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gianpaolo Fogliatto has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Anna De Ponti

    Authors' Affiliations: 1Nerviano Medical Sciences S.r.l. and 2Accelera S.r.l., Nerviano (MI), Italy

    1 shared publication
  • Anna Degrassi

    Authors' Affiliations: 1Nerviano Medical Sciences S.r.l. and 2Accelera S.r.l., Nerviano (MI), Italy

    1 shared publication
  • Antonella Isacchi

    Authors' Affiliations: 1Nerviano Medical Sciences S.r.l. and 2Accelera S.r.l., Nerviano (MI), Italy

    1 shared publication
  • Antonella Isacchi

    NMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy

    1 shared publication
  • Arturo Galvani

    Authors' Affiliations: 1Nerviano Medical Sciences S.r.l. and 2Accelera S.r.l., Nerviano (MI), Italy

    1 shared publication
  • Barbara Valsasina

    Authors' Affiliations: 1Nerviano Medical Sciences S.r.l. and 2Accelera S.r.l., Nerviano (MI), Italy

    1 shared publication

Latest Publications

  • Open Access

    Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma

    by Serena Pellegatta, Lorella Valletta, Cristina Corbetta, Monica Patanè, Ileana Zucca, Federico Riccardi Sirtori, Maria Grazia Bruzzone, Gianpaolo Fogliatto, Antonella Isacchi, Bianca Pollo, et al.

    The R132H mutation of cytosolic isocitrate dehydrogenase (IDH1) is present in the majority of low grade gliomas. Immunotherapy in these tumors has an interesting, still unexploited, therapeutic potential, as they are less immunosuppressive than glioblastomas. Using site-directed mutagenesis we introduced the R132H mutation into the murine glioma cell line GL261, creating mIDH1-GL261. Presence of the mutation was confirmed by immunoblotting and production of the oncometabolite 2-hydroxyglutarate (2HG), demonstrated by mass spectrometry (LC-MS/MS) performed on cell supernatant. In vitro mIDH1-GL261 had different morphology but similar growth rate than parental GL261 (p-GL261). After intracranial injection, MRI suggested that the initial growth rate was slower in mIDH1-GL261 than p-GL261 gliomas but overall survival was similar. mIDH1-GL261 gliomas showed evidence of R132H expression and of intratumoral 2HG production (evaluated by MRS and LC-MS/MS). Immunizations were performed nine days after intracranial implantation of mIDH1- or p-GL261 cells by three subcutaneous injections of five different peptides encompassing the IDH1 mutation site, all emulsified with Montanide ISA-51, in association with GM-CSF. Control mice were injected with four ovalbumin peptides or vehicle. Mice with mIDH1-GL261 but not p-GL261 gliomas treated with mIDH1 peptides survived longer than controls; 25% of them were cured. Immunized mice showed higher amounts of peripheral CD8+ T cells, higher production of IFN-γ, and evidence of anti-mIDH1 antibodies. Immunizations led to intratumoral up-regulation of IFN-γ, granzyme-b and perforin-1 and down-regulation of TGF-β2 and IL-10. These results support the translational potential of immunotherapeutic targeting of gliomas carrying IDH1 mutations.


  • Open Access

    NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases

    by Gianpaolo Fogliatto, Laura Gianellini, Maria G. Brasca, Elena Casale, Dario Ballinari, Marina Ciomei, Anna Degrassi, Anna De Ponti, Massimiliano Germani, Marco Guanci, et al.

    Purpose: Recent developments of second generation Hsp90 inhibitors suggested a potential for development of this class of molecules also in tumors that have become resistant to molecular targeted agents. Disease progression is often due to brain metastases, sometimes related to insufficient drug concentrations within the brain. Our objective was to identify and characterize a novel inhibitor of Hsp90 able to cross the blood–brain barrier (BBB). Experimental Design: Here is described a detailed biochemical and crystallographic characterization of NMS-E973. Mechanism-based anticancer activity was described in cell models, including models of resistance to kinase inhibitors. Pharmacokinetics properties were followed in plasma, tumor, liver, and brain. In vivo activity and pharmacodynamics, as well as the pharmacokinetic/pharmacodynamic relationships, were evaluated in xenografts, including an intracranially implanted melanoma model. Results: NMS-E973, representative of a novel isoxazole-derived class of Hsp90 inhibitors, binds Hsp90α with subnanomolar affinity and high selectivity towards kinases, as well as other ATPases. It possesses potent antiproliferative activity against tumor cell lines and a favorable pharmacokinetic profile, with selective retention in tumor tissue and ability to cross the BBB. NMS-E973 induces tumor shrinkage in different human tumor xenografts, and is highly active in models of resistance to kinase inhibitors. Moreover, consistent with its brain penetration, NMS-E973 is active also in an intracranially implanted melanoma model. Conclusions: Overall, the efficacy profile of NMS-E973 suggests a potential for development in different clinical settings, including tumors that have become resistant to molecular targeted agents, particularly in cases of tumors which reside beyond the BBB. Clin Cancer Res; 19(13); 3520–32. ©2013 AACR.